| Assay ID | Title | Year | Journal | Article |
|---|
| AID314397 | Volume of distribution in CD1 mouse at 2 mg/kg, iv and 10 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID331271 | Inhibition of FMS | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
| Structure-based optimization of a potent class of arylamide FMS inhibitors. |
| AID696437 | Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization | 2011 | Journal of medicinal chemistry, Nov-24, Volume: 54, Issue:22
| Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ |
| AID331272 | Antiproliferative activity against BMDM cells | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
| Structure-based optimization of a potent class of arylamide FMS inhibitors. |
| AID314399 | Inhibition of Kit after 30 mins by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314398 | Oral bioavailability in CD1 mouse at 10 mg/kg | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314403 | Inhibition of IRKbeta after 20 mins by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314401 | Inhibition of TrkA after 27 mins by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314400 | Inhibition of Axl after 11 mins by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314406 | Reduction in pannus formation in mouse CIA model BID for 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314396 | Cmax in CD1 mouse at 2 mg/kg, iv and 10 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314407 | Reduction in bone destruction in mouse CIA model BID for 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314404 | Reduction in progression of collagen-induced arthritis scores in mouse CIA model at 30 mg/kg, po bid | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314405 | Reduction in progression of collagen-induced arthritis scores in mouse CIA model at 5 mg/kg, po bid | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314395 | Half life in CD1 mouse at 2 mg/kg, iv and 10 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID658392 | Inhibition of AXL kinase | 2011 | ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
| Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. |
| AID314408 | Reduction in cartilage destruction in mouse CIA model BID for 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314392 | Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID314402 | Inhibition of Flt3 after 25 mins by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1798844 | FMS Enzyme Inhibition Assay from Article 10.1021/jm801406h: \\Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors (dagger).\\ | 2009 | Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
| Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |